Zoetis Inc (NYSE:ZTS) – Research analysts at Gabelli boosted their FY2018 earnings per share (EPS) estimates for shares of Zoetis in a research report issued on Friday, according to Zacks Investment Research. Gabelli analyst K. Kedra now forecasts that the company will earn $3.05 per share for the year, up from their prior forecast of $3.00. Gabelli also issued estimates for Zoetis’ FY2020 earnings at $3.90 EPS and FY2022 earnings at $4.75 EPS.
Zoetis (NYSE:ZTS) last released its earnings results on Thursday, February 15th. The company reported $0.69 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.66 by $0.03. Zoetis had a return on equity of 65.96% and a net margin of 16.28%. The firm had revenue of $1.46 billion during the quarter, compared to analysts’ expectations of $1.40 billion. During the same period in the previous year, the firm posted $0.47 EPS. Zoetis’s revenue for the quarter was up 14.3% on a year-over-year basis.
Zoetis (ZTS) traded down $0.24 on Monday, reaching $84.35. The company’s stock had a trading volume of 1,794,705 shares, compared to its average volume of 3,050,000. The company has a current ratio of 3.85, a quick ratio of 2.55 and a debt-to-equity ratio of 2.77. Zoetis has a 12-month low of $52.25 and a 12-month high of $85.54. The stock has a market cap of $41,100.00, a P/E ratio of 38.69, a PEG ratio of 1.89 and a beta of 0.97.
The business also recently announced a quarterly dividend, which will be paid on Friday, June 1st. Stockholders of record on Friday, April 20th will be given a dividend of $0.126 per share. The ex-dividend date of this dividend is Thursday, April 19th. This represents a $0.50 dividend on an annualized basis and a dividend yield of 0.60%. Zoetis’s payout ratio is 22.94%.
In other news, EVP Roxanne Lagano sold 35,663 shares of the stock in a transaction on Wednesday, February 21st. The shares were sold at an average price of $81.02, for a total transaction of $2,889,416.26. Following the completion of the sale, the executive vice president now owns 49,919 shares of the company’s stock, valued at $4,044,437.38. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Roman Trawicki sold 23,885 shares of the firm’s stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $82.00, for a total transaction of $1,958,570.00. The disclosure for this sale can be found here. Insiders sold 105,569 shares of company stock worth $8,594,429 over the last 90 days. 0.31% of the stock is currently owned by company insiders.
A number of hedge funds have recently added to or reduced their stakes in the business. Dynamic Technology Lab Private Ltd grew its holdings in shares of Zoetis by 7.3% during the 2nd quarter. Dynamic Technology Lab Private Ltd now owns 5,901 shares of the company’s stock valued at $368,000 after purchasing an additional 401 shares during the last quarter. Quantbot Technologies LP acquired a new position in shares of Zoetis during the 3rd quarter valued at $3,972,000. Daiwa SB Investments Ltd. lifted its position in shares of Zoetis by 92.0% during the 4th quarter. Daiwa SB Investments Ltd. now owns 18,152 shares of the company’s stock valued at $1,308,000 after acquiring an additional 8,696 shares during the period. BLB&B Advisors LLC lifted its position in shares of Zoetis by 5.2% during the 4th quarter. BLB&B Advisors LLC now owns 50,460 shares of the company’s stock valued at $3,635,000 after acquiring an additional 2,478 shares during the period. Finally, King Luther Capital Management Corp raised its holdings in Zoetis by 3.7% during the third quarter. King Luther Capital Management Corp now owns 1,264,164 shares of the company’s stock worth $80,603,000 after buying an additional 44,697 shares during the last quarter. 92.45% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: “FY2018 EPS Estimates for Zoetis Inc (ZTS) Lifted by Gabelli” was reported by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this story on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this story can be read at https://stocknewstimes.com/2018/03/14/gabelli-weighs-in-on-zoetis-incs-fy2018-earnings-zts.html.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.